Reports Q2 revenue EUR 260.8M vs. EUR 128.7M last year. “In the second quarter, we took significant steps to advance BioNTech (BNTX) into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “We entered into a collaboration with BMS to accelerate and expand the development of our PD-L1xVEGF-A bispecific antibody candidate BNT327 and announced a strategic transaction to acquire CureVac to complement our own capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. These transformative transactions contribute to our mission of delivering truly transformative options for patients in need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BNTX Earnings this Week: How Will it Perform?
- MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
- BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment
- UK appeals court rules Moderna patent valid and infringed by Pfizer, BioNTech
- BioNTech’s Promising Phase II Trial: RO7198457 vs. Watchful Waiting in Colorectal Cancer